| __timestamp | Amneal Pharmaceuticals, Inc. | GSK plc |
|---|---|---|
| Wednesday, January 1, 2014 | 335989000 | 7323000000 |
| Thursday, January 1, 2015 | 367054000 | 8853000000 |
| Friday, January 1, 2016 | 420770000 | 9290000000 |
| Sunday, January 1, 2017 | 507476000 | 10342000000 |
| Monday, January 1, 2018 | 946588000 | 10241000000 |
| Tuesday, January 1, 2019 | 1273376000 | 11863000000 |
| Wednesday, January 1, 2020 | 1364130000 | 11704000000 |
| Friday, January 1, 2021 | 1324696000 | 11603000000 |
| Saturday, January 1, 2022 | 1427596000 | 9554000000 |
| Sunday, January 1, 2023 | 1573042000 | 8565000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for GSK plc and Amneal Pharmaceuticals, Inc. from 2014 to 2023. Over this period, GSK consistently maintained a higher cost of revenue, peaking in 2019 with approximately $11.86 billion. However, a notable decline to around $8.57 billion in 2023 suggests a strategic shift or market adaptation. In contrast, Amneal Pharmaceuticals, Inc. demonstrated a steady increase, with its cost of revenue rising by nearly 370% from 2014 to 2023, reaching approximately $1.57 billion. This growth trajectory highlights Amneal's expanding market presence and operational scaling. Understanding these trends provides valuable insights into the strategic maneuvers of these pharmaceutical giants, offering a glimpse into their financial health and market strategies.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and GSK plc's Expenses
Cost Insights: Breaking Down GSK plc and United Therapeutics Corporation's Expenses
GSK plc or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost of Revenue: Key Insights for GSK plc and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: GSK plc and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Catalent, Inc. and Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Amneal Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. vs Perrigo Company plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Amneal Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Amneal Pharmaceuticals, Inc. vs MiMedx Group, Inc.